Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synsam ABCHIX:SYNSAS 85 EV-to-EBITDA is 5.90 as of Aug. 20, 2026, which is 16% below its 10-year median of 7.01. GuruFocus rates CHIX:SYNSAS with a GF Score™ of 85/100 and a GF Value™ of kr66.63. The stock has 1 warning sign investors should review. Among 515 Medical Devices & Instruments companies, Synsam AB ranks better than 85.44% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Synsam AB's enterprise value is kr10,930 Mil.
Synsam AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr1,852 Mil. Therefore, Synsam AB's EV-to-EBITDA for today is 5.90.
The historical rank and industry rank for Synsam AB's EV-to-EBITDA or its related term are showing as below:
CHIX:SYNSAs'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.36 Med: 7.01 Max: 11.89
Current: 5.9
During the past 8 years, the highest EV-to-EBITDA of Synsam AB was 11.89. The lowest was 5.36. And the median was 7.01.
CHIX:SYNSAs's EV-to-EBITDA is ranked better than 85.44% of 515
companies
in the Medical Devices & Instruments industry
Industry Median: 15.16
vs CHIX:SYNSAs: 5.90
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Synsam AB's share price for today is kr59.80.
Synsam AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr3.460.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Synsam AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:SYNSAS vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Synsam AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synsam AB EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Synsam AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Synsam AB's EV-to-EBITDA falls into.
Synsam AB's current Enterprise Value is kr10,930 Mil.
Synsam AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1,852 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synsam AB (CHIX:SYNSAS) has a EV-to-EBITDA of 5.90 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Synsam AB. This is 16% below median its historical median of 7.01. Over the past decade, Synsam AB's EV-to-EBITDA has ranged from 5.36 to 11.89. According to the industry distribution chart, Synsam AB ranks #75 out of 515 companies in the Medical Devices & Instruments industry, placing it in the top 14.6%.
Is Synsam AB's EV-to-EBITDA too high?
Synsam AB's current EV-to-EBITDA of 5.90 is 16% below median its 10-year median of 7.01. Over the past 10 years, this metric has ranged from a low of 5.36 to a high of 11.89. The Medical Devices & Instruments industry median EV-to-EBITDA is 15.16. Synsam AB's value of 5.90 is 61.1% below this industry median. Based on the distribution chart, Synsam AB ranks #75 out of 515 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Synsam AB has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Synsam AB's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Synsam AB ranks #75 out of 515 companies for EV-to-EBITDA. This places Synsam AB in the top 15% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 15.16. Synsam AB's value of 5.90 is 61.1% below this benchmark. Historically, Synsam AB's own EV-to-EBITDA has ranged from 5.36 to 11.89 over the past decade. While the company's 10-year median is 7.01 vs. the industry median of 15.16, Synsam AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 15.16, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synsam AB's current EV-to-EBITDA of 5.90 is 61.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Synsam AB. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 15.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synsam AB's current EV-to-EBITDA is 5.90, which is 16% below median its own 10-year median of 7.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synsam AB stock overvalued right now?
Synsam AB (CHIX:SYNSAS) has a current EV-to-EBITDA of 5.90. The stock's GF Value™ is kr66.63, compared to a current price of kr59.80 — trading 10.3% below its estimated fair value. The current EV-to-EBITDA is 5.90, which is 16% below median its 10-year median of 7.01 and 61.1% below the Medical Devices & Instruments industry median of 15.16. Synsam AB's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Synsam AB (CHIX:SYNSAS), the current EV-to-EBITDA is 5.90 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synsam AB (CHIX:SYNSAS) Overvalued in 2026?
Based on GuruFocus' analysis, Synsam AB stock appears to be undervalued.
The current stock price of kr59.80 is trading 10.3% below its estimated GF Value™ of kr66.63.
Key valuation signals for CHIX:SYNSAS:
EV-to-EBITDA: 5.90 (16% below median its 10-year median of 7.01)
GF Value™: kr66.63 vs. price of kr59.80 (10.3% below fair value)
Industry Position: 61.1% below the Medical Devices & Instruments median (#75 of 515)
No single metric tells the full story. See the CHIX:SYNSAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synsam AB is a lifestyle company in optics and eye health in the Nordic region. The company offers various products and services in physical and digital stores, such as eye examinations, spectacles, sunglasses, sports spectacles, contact lenses, and accessories in optical retail, as well as spectacles subscriptions and related services under the name Synsam Lifestyle. Its stores are operated under the Synsam brand in Sweden, Norway, and Finland, and under the Profil Optik brand in Denmark and Iceland. The company comprises four segments: Sweden, which generates key revenue, Denmark, Norway, and Finland.
85GF Score
Get the complete analysis for CHIX:SYNSAS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:SYNSAS has been successfully added to your 
